Ida, thank you for your detailed response about
Riluzole. I plan on gathering as much information as I can before I enter
a study group.
At 13:52 22-3-99 -0800, ERVIN J MCCARTHY
wrote:
>Does anyone on the list have information on Riluzole? I have
been asked to
>join a group study on the drug. I believe it is in
third phase study. I
>recall someone in the list had been involved in
a previous group study. Any
>information would be helpful. Thank
you.
>
>[log in to unmask]
Erwin,
Riluzole
or Rilutex is an anti-glutamate. It diminishes the influence of the
neurotransmitter
glutamate,which has an activating role in the Striatum.
They are by some researchers
believed to be to active in PWP's and to
have a crucial role in dyskinesia especially
the leva-dopa induced ones.
The nuclei in which the glutamates are most activ are the same that
as
are partly destroyed by pallidotomy. But it is not in the first place
because of
that aspect why trials are run. It has been proven to have a
neuroprotective effect
for ALS patients and that has in the first place
attracted the Parkinson researchers,
because it might have the same
neuroprotective effect for PWP,s. I am not sure but I
remember that for
the trials to come, starting PWP's have been asked to participate, so
the
only outcome of the research will be about its neuroprotective effect.
I
regret that, because I am more interested in its potential anti-diskinetic
power.
Next to the mentoned
effects is Riluzole, if used in higher dosis a paini killer a tranquiliser
and an anti -convulsive.
With theses URL.s more info can be
retrieved,
ida
http://parkinson.org/plll.htm
WWW.rorer.com/PATIENTS_FAMILIES/trials/trials.rilutek.htm
http://www.rpr.rpna.com/US/rilutek/ppi.html
http://www.druginfonet.com/rilutek.htm
http://neuro-www.mgh.harvard.edu/forum/ALSF/11.13.9812.56PMRilutek.html
http://www.rpr.rpna.com/health_professionals/diseaseaware/rilutek.htm
--------------------------------------------------------------
Vriendelijke
Groeten / Kind regards,
Ida Kamphuis mailto:
[log in to unmask]